Showing results (201-210 of 225) with videos related to
Sort By:
Pageof 23
The New England Journal of Medicine|July 1, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell CarcinomaToni K Choueiri, Robert J Motzer, Jose A Karam, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.Anti-Cancer Drugs|May 31, 2018
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinomaRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.Nature Medicine|January 28, 2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trialSerena Porcari, Chiara Ciccarese, Vitor Heidrich, et al.Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.The Oncologist|October 6, 2025
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global surveyEnrique Grande, Joaquim Bellmunt, Syed A Hussain, et al.Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.Pageof 23